Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
44.03
-0.08 (-0.18%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Global Breast Cancer Market Size Projected To Hit $70 Billion in Revenues By 2030
May 05, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:NNOX),(NASDAQ:SNGX),(NASDAQ:CRDF) EQNX::TICKER_END
Via
FinancialNewsMedia
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
May 03, 2023
From
Bristol Myers Squibb
Via
Business Wire
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
May 02, 2023
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers
Via
MarketBeat
Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference
May 02, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol-Myers Squibb Company (NYSE: BMY) Highlighted for Surprising Price Action
May 01, 2023
Via
Investor Brand Network
Exposures
COVID-19
U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
May 01, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate
May 01, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
April 27, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Leadership Transition Plan
April 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
April 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
April 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
Why Legend Biotech Stock Is Having Its Best Month Yet
April 25, 2023
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.
Via
MarketBeat
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
April 17, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
March 31, 2023
From
Bristol Myers Squibb
Via
Business Wire
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial
March 30, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
March 28, 2023
From
Bristol Myers Squibb
Via
Business Wire
BioNTech Is Ripe For A Rebound In 2023
March 27, 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
March 22, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
These Are The Top 3 Large Caps For Yield And Dividend Growth
March 21, 2023
You can use Marketbeat's Dividend Screener to find top dividend growth stocks with yields above 3% and value for investors.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
March 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023
March 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
March 03, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
March 03, 2023
From
Bristol Myers Squibb
Via
Business Wire
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
March 02, 2023
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
February 28, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in Cowen’s 43rd Annual Health Care Conference
February 28, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
February 27, 2023
From
Bristol Myers Squibb
Via
Business Wire
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
February 22, 2023
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END
Via
FinancialNewsMedia
Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial
February 17, 2023
From
Bristol Myers Squibb
Via
Business Wire
Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation (AFib) and its Symptoms
February 16, 2023
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.